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Low dose qumidme-mexiktine combination therapy was 
cornpa& with quinidioe monotherapy in 15 patients with 
frequent ventricular premature complexes and IOIPSUS- 
mined ventricular tachycardia in a dose escalation cross- 
over study. Qra! combination therapy was initiated With 
quhtidme gluconate (165 mg) plus mexiletiue (150 mg) 
every 8 h. If ventricular premature Complexes were not 
suppressed r80% and nousustained ventricular tachycar- 
dia ~90%) the dose was increased to a maximum of 330 mg 
of quimdine plus 209 mg of mexhetine. Quinidiie mono- 
therapy was hdtiated with 339 mg and escalated to a 
maximum of 660 mg every 8 b if criteria for effectiveness 
were not met. 
Combiition quinidine-mexiletine therapy suppressed 
80% of ventricular premature complexes in 13 of 14 
patients and suppressed lOO% of episodes of ventricular 
tachycardia in 6 of 8 patients (mean quinidine dose 2Otl f 
70 mg; mean mexiletine dose 1 t 24 mg every 8 h). The 
Clinical reports (I-5) of the effectiveness of antiarrhythmic 
therapy note that combining agents with varied electrophys- 
ioIogic properties often results in more profound antiarrhyth- 
mic action than does monotherapy. Quinidine-mexiletine has 
been shown (3-5) to be an effective combination against 
sustained ventricular tachycardia and inducible ventricular 
arrhythmias, even in patients refractory tomonotherapy and 
at risk of sudden cardiac death. Perhaps because of their 
serious nature, sustained ventricular rhythmias have been 
treated with relatively arge doses of combination quinidine- 
mexiletine, quivalent tomonotherrpy. Theoretically, how- 
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mean effective trougb qub&lme and mexiletine co~ce~tra- 
tion was 1.0 f 0.7 and 0.9 f 0 
~onothe~py was less efkctive; th 
suppression of ventricular tachycardia 
The mean quinidine mo~otbera~y dose 
was 462 i 155 mg every g h; the mean quinidine concen- 
tration was 1.8 9 0.8 &ml. 
Adverse systemic effects occurred in 3 patiemts on 
quinidine.mexiietine therapy and in 11 on quinidine mono- 
therapy. Neither treatment prolonged 
vals, but monotherapy prolonged the QTc 
0.05); both treatments prolonged the cou 
(p < 0.05). Low dose quinidine-mexiletine is more effective 
and better tolerated than are standard doses of quini- 
time. 
(J Am Cdl Cardiol1990;15:1138-45) 
ever, if quinidine and mexiletine are synergistic, lower 
doses used in combination should be more effective than 
monotherapy and associated with fewer adverse ffects. 
This position is taken by the U.S. Food and Drug Adminis- 
tration when recommending approval of combination ther- 
apy. Accordingly, this project was initiated to compare the 
effect of the low end of the dose response for quinidine- 
mexiletine combination therapy with that of quinidine mono- 
therapy on frequency of ventricular premature complexes 
and nonsustained ventricular tachycardia n patients with 
symptomatic arrhythmias. 
It was our goal to 1) determine whether low dose com- 
bination treatment effectively suppresses arrhythmias; 2)
evaluate the effect of quinidine-mexiletirre combination 
therapy and quinidine monotherapy on arrhythmia fre- 
quency and the electrocardiogram (ECG); and 3) assess the 
frequency of adverse ffects. To this end, I5 patients with 
symptomatic ventricular premature corn 
rolled in a placebo-controlled, single-blind, randomized 
crossover trial. The protocol was implemented using a 
crossover design to minimize patient differences and, thus, 
0735-1097/90/$3.50 
prescribed for treatment other than ventricular 
they had evidence of t 
tachycardia; 4) known intolerance, previous 
infarction within 3 months of study; or 6) severe renal or 
hepatic disease. 
pression of ventricular p 
suppression f nonsustaine 
first (lowest) dose of combi 
mg, @us mexiletine, 150 m 
suppression of ventricula 
the dose was increased to quinidine, 330 mg, plus mexiletine, 
150 mg (mid dose), and then ‘nidine, 330 mg, plus mexi- 
letine, 200 mg (highest dose). xiletine in capsules of IO0 
1.50 mg and quinidine gluconate blets. each 330 mg 
rner-C~~~cott), wereprovided by hringer-~ngelheim. 
initial dose of oral quinidine glut e (iowest dose) for 
monotherapy was 330 mg every 8 h, then 495 mg (mid dose) 
and was escalated to a maximum of 660 mg (highest dose) 
every 8 h if there was ~80% suppression of ventricular 
premature complexes and treatment was tolerated. Patients 
received a dose for 272 h before obtaining a 24 h ambulatory 
KG to evaluate its effect; at that time, the 12 lead ECG. 
blood chemistry values and drug concentration were also 
obtained. 
Ambulatory 24 h ECG recordin . The ambulatory ECG 
was recorded uring a drug-free period (2), during each dose 
escalation (1-3) and during washout (I). During dose esca- 
intervals), frequency of vent 
episodes of ve~t~c~~ar tachy 
ermine the relation of pretreatment ventric- 
a~ncte~ist~cs. The tudy group consisted of I5 
patients (I i women, 4men); 5 had cardiomyopathy, 5 had a 
primary electrical bnormality, 2 had ischemic heart disease, 
2 had hypertensive h art disease and I had mitral valve 
prolapse. Ejection fraction was determined in 13 pati 
either by radionuclide angiogram (n = 12) or by echoc 
gram (n = 1). The mean pretreatment ejection fraction was 
52% + 14% (range 23% to 67%, median 55%). The 
pretteatment cardiothoracic ratio on the chest X-ray til 
14 patients was 0.5 1 + 0.09. Ten patients were taking one or 
more cardiac medications: ix 
enzyme inhibitor, four a beta-b1 
coside, two a potassium supplement, o 
antagonist and one warfarin. None of the patients had 
previously been treated with quinidine or mexiletine. xcept 
one who had sporadically taken quinidine without 
efficacy. 
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Table 1. Electrocardiographic Intervals in IS Patients 
PR Qus QT, RV 
Q + M We) 182 -+ 27 92 f 21 432 k 29 476 -L 57 
Q+M(post) it-22 91 -c 21 433 f 28 531 It 80* 
Mean A _, 1 55 
Q (pre) 176 2 20 89 f 22 408 f 35 476 k 57 
Q (post) I80 + 24 9lrt21 448r44* 545 + 51* 
Mean A 4 2 40 69 
*p < 0.05 predrug (pre) versus postdrug (post). All values are in ms. M = 
mexiletine; Q = quinidine; RV = coupling interval: A = change. 
Ele&ocardiographic intervals. No significant difference 
was noted for pretreatment PR, QRS, QTc, RR or RV 
intervals before combination therapy or monotherapy (Table 
I). NO significant change from mean pretreatment RR or 
mean QRS intervals occurred after quinidine-mexiletine 
combination therapy or quinidine monotherapy. The pre- 
treatment QTc interval did not change significantly after 
combination therapy and did not prolong to ~~500 ms. 
However, quinidine monotherapy rolonged the QTc inter- 
val significantly, from 408 2 35 to 448 f 44 ms (p C 0.05). 
and in two patients, the QTc interval prolonged to2500 ms. 
One patient developed first degree AV block during both 
treatments, In one patient atrial fibrillation converted to 
sinus rhythm during quinidine-mexiletine herapy; in this 
patient conversion had not occurred uring the initial period 
of randomization to quinidine monotherapy. 
The mean drug-free coupling interval (RV interval), mea- 
sured in I2 patients, was 476 f 57 ms. Quinidine-mexiletine 
combination therapy significantly (p< 0.05) prolonged the 
mean RV interval to 531 f 80 ms, as did quinidine mono- 
therapy (545 Z!C 51 ms, p < 0.05). No significant difference 
was found between the effect of quinidine-mexiletine com- 
bination therapy and monotherapy on the RV interval (Table 
1). 
Meet of quiaidine=mexiletine on arrhythmia (Tables 2 and 
3). There was no difference inthe frequency of ventricular 
premature complexes before the patients received quinidine- 
mexiletine combination therapy or quinidine monotherapy 
(p = NS) (Fig. I). Baseline frequency of ventricular prema- 
ture complexes before quinidine-mexiletine combination 
therapy averaged 209 f 327/h (range 12 to 1,263, median 
121). Fourteen patients received quinidine-mexiletine ther- 
apy; 13 of these patients had >80% suppression f ventric- 
ular premature complexes and 1 patient had 59% suppres- 
sion. After treatment, the mean frequency of ventricular 
premature complexes was 23 + 33/h (range 1to 104, median 
17) (P < 0.05); the mean percent suppression was 88% + 11 
(median 93%) (Table 2). 
There was no difference inthe frequency of episodes of 
ventricular tachycardia before receiving quinidine-mexilet- 
ine combination therapy or quinidine monotherapy (p = 
NS). Eight patients receiving quin~d~~e-~ex~!eti~e therapy 
had nonsustained ventricular tachycardia or ventricular 
rhythm (<IO0 beatsimin) before treatment fre- 
quency of episodes of 277 2 479 (range 1to I, n 7). 
After treatment, sixof the eight patients had nonsustained 
ventricular tachycardia abolished; two others had 98% and 
99% suppression (p< 0.05), respectively. The longest runs 
and the fastest rates of ventricular tachycardia decreased in 
these two patients (Table 3). The mean frequency of ventric- 
ular tachycardia episodes after treatment was 3 2 9 (range 0
to 26, median 0). mean percent abo~~t~o~ 1 
100%) (p c 0.05) (Table 3). 
Effect of quinidine mo~othera 
and 3). Baseline frequency of ventricular premature com- 
plexes before administration f quinidine monotherapy av- 
eraged 248 2 285/h (range 16 to 971. median 125). Five of the 
15 patients who received quinidine monotherapy had >80% 
suppression f ventricular premature complexes; in 4 others 
the treatment had an antiarrhythmic effect but did not reach 
the 80% suppression criterion (range 69% to 74%). After 
treatment, the mean frequency of ventricular premature 
complexes was 129 f 169/h (range I to 
0.05); mean percent suppression was 52 
to 98%, median 78%) (Table 2). The 
mexiletine combinz?ion therapy on the suppression ofven- 
tricular premature complexes was more marked than that of 
quinidine monotherapy (p < 0.05). 
Nine patients had episodes of nonsustained ventricular 
tachycardia or ventricular rhythm before quinidine mono- 
therapy (mean frequency 393 + 905, range 1 to 2,762, median 
8). After treatment, two had nonsustained ventricular tachy- 
cardia bolished. Quinidine shortened runs and slowed the 
rate of ventricular tachycardia in all but wo patients (p < 
0.05). One patient had a >lO-fold increase in episodes of 
nonsustained ventricular tachycardia and was considered to
have proarrhythmia; after treatment, the m an frequency of
ventricular tachycardia episodes was 1,050 f 2,928 (range 0
to 8,842, median 1); mean percent suppression was - 150 2 
555% (range -1607% to lOO%, median 75%). Quinidine- 
mexiletine therapy was more effective than quinidine ther- 
apy in suppressing episodes of nonsustained ventricular 
tachycardia (p < 0.05). 
Dose and drug concentration after combination therapy 
(Fig. 2). The mean dose of combination treatment in 14 
prtients was low: quinidine, 200 ? 70 mg, and mexiletine, 
146 + 24 mg every 8 h (Table 2). Ten of the I3 patients who 
responded to quinidine-mexiletine combination therapy did 
so at: quinidine, 165 mg, and mexiletine, 150 mg. One patient 
takingquinidine, I65 mg, had 80% suppression f ventricular 
premature complexes even after mexiletine was titrated 
down to 100 mg every 8 h; another respo~de 
330 mg, and mexiletine, 150 mg; and another to quinidine, 
330 mg, and mexiletine, 280 mg. The one patient who did not 
achieve 80% suppression had adverse ffects with quinidine, 
JACC Vol. 15, No. 5 
Patient 
No. 
Dose 
bng) 
VPCih 
(pre) 
VPC!h 
(gosO R 
~uinidine-~exi~etioe 
VI VT 
Episode. Episodes 
(pre) ! QOSt 1 
I 330 57 
2 495 94 
3 330 5u9 
4 330 38 
5 330 28S 
6 660 16 
7 330 22 
8 330 178 
9 3305 508 
IO 495 153 
Ii 660 27 
12 660 113 
I3 660 97) 
14 330 425 
I5 660 I25 
6 
$11 ._i 
207 
6 
127 
5 
I 
24 
131 
212 
6 
96 
615 
346 
24 
89 0 
-30 0 
71 51X 
84 1 
s5 4 
69 0 
98 0 
81 0 
14 0 
-45 4 
78 3 
I5 IO 
37 2.162 
19 226 
83 8 
0 
0 
X.842 
2 
0 
0 
3 
0 
0 
I 
4 
I7 
583 
0 
0 
0 
-1.667 
-100 
IO0 
0 
0 
0 
0 
75 
80 
60 
99 
-I58 
100 
Mean 462 248 12911 s2 393 I.050 -150 
+SD 155 285 169 44 905 2,928 555 
Median 330 I25 96 78 8 I 75 
*p < 0.05 = ventricular premature complexes (VPC) pre versus post quinidine-mexiletine: +p < 0.05 = ventricular premature complexes qoinidi~e-mexilel~ae 
(post) versus quinidine (post): $p < 0.05 j ventricular tachycardia (VT) quinidine-mexiletine (post) versus quinidine (post); lpatient received maximal dose of 
660 mg every 8 R quinidine. but developed rash and could not have efficacy tested on this dose: lip < 0.05 = venlricular Pr2matUr2 COmPl2X2S Pr2 v2rSUS POSt 
330 mg, an mg. The effective trough 
Rce~tratio~ n co~bi~tion 
I (range 0 to 3.21, and tro 
tion was 0.9 + 0.4 j&ml (ra 
describes the log dose-~)rob~t c 
dose-effect re~atiom between qu 
ose and drug c~~~~n~~~~~~ 
mean quinidine monotherapy dose in I5 patients was 462 2 
155 mg every 8 h (range 330 to 660, median 330) (Table 2) and 
the Lrough concentration was 1.8 + 0.8 ,ugI 
s taking quinidine, 330 
adverse &e&s (n = 3). Eight pati 
80% suppression after 330 mg req 
in dose: one showed im but four did not after 
q~~i~id~~e, 660 mg every 8 
patients who received quinid 
who received quinidine, 64 
dose for the five patients with >80% suppression was 3% 2 
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T&k 3. Effect on Frequency and Rate of Ventricular Tachycardia 
Patient 
No. Episodes 
Pre-treatment Post-treatment 
Longest VT Fastest VT Longest VT Fastest VT 
([no. of beats]/[beatslmin]) ([no. of beatsll]beatslminl] Episodes ([no. of beats]/[beats/min]) ([no. of beats]/[beats/min]) 
Quinidine-Mexiletine 
3 1,042 171107 31117 26 g/112 g/112 
4 I 3l78 3/78 0 - 
5 0 0 - 
8 I 31121 31121 0 - - 
10 3 41158 41158 0 - 
I1 5 51172 51172 0 - - 
12 0 - 0 - - 
13 l,W 61153 61153 0 
I4 95 91216 91216 1 31131 31131 
15 10 4169 31149 (5 
Mean 277 6/134 51146 3* 61122t 6/122$ 
+,SD 479 8/50 2l41 9 4113 4113 
Quinidine 
3 518 221125 81132 8,842 701110 31134 
4 4 4188 4188 2 3157 3157 
5 4 3/121 3021 0 - 
8 0 0 
10 4 41143 41143 1 31120 31120 
11 3 51174 5!174 1 41112 41112 
12 10 31125 31125 4 3018 3018 
13 2,762 6ll32 41158 17 4199 31102 
14 226 III!94 31240 583 19157 41264 
15 8 3!147 31147 0 - 
Mean 393 71139 41148 1,050 15196s 31121)) 
-+SD 905 6/31 2142 2,928 25128 0.5 
*p < 0.5 = ventricular tachycardia (VT). quinidine-mexiletine (post) versus quinidine (post]; tp =z 0.05 F rate of longest ventricular tachycardia episode, 
quinidine-mexiletine pre versus post; Sp < 0.05 = rate of fastest ventricular tachycardia episode, quinidine-mexiletine pre versus post; !Ip +C 0.05 = rate of longest 
ventricular tachycardia episode, quinidine pre versus post; I]p < 0.05 = rate of fastest ventricular tachycardia episode, quinidine pre versus post. Abbreviations 
as in Table 2. 
148 mg every 8 h (range 330 to 660, median 330); the effective 
trough quinidine concentration was 1.7 f 0.8 &ml (range 
0.7 to 2.8). A linear elation between the quinidine dose and 
concentration (r = 0.72, p < 0.05) was observed. There was 
a significant difference between the quinidine concentration 
Figure 1. Frequency of ventricular premature complexes (VPC) per 
hour (log scale) on the predrug versus washout 24 h ambulatory 
electrocardiogram. There is no difference b tween frequency during 
the two periods (r = 0.90). 
Km 
VPClhr 
Pre-drug 
i 100 . 
IO 100 1000 
VPC/hr - Wolrhout 
attained after combination versus monotherapy (p< 0.05). 
The average trough quinidine concentration i  both treat- 
ment limbs was lower than the conventional therapeutic 
range (2 to 5 &ml). Precise timing of blood sampling after 
drug administration in a relatively small outpatient trial 
could have accounted for the low and variable quinidine 
concentrations. The effective quinidine concentration range 
after quinidine-mexiletine administration could be lower 
than the currently accepted therapeutic range, but this will 
require further evaluation. 
Adverse systemic and cardiac effects (Table 4). One or 
more adverse systemic effects were attributed to combina- 
tion quinidine-mexiletine, a dtherapy was discontinued in
three patients because of headache, cough, insomnia, ner- 
vousness or dry mouth. In retrospect, cough may have been 
caused by concomitant therapy with a converting enzyme 
inhibitor. MO adverse cardiac effects were noted during 
treatment with quinidine-mexiletine combination therapy. 
During quinidine monotherapy, adverse systemic OF car- 
and quinidine monothera 
dim efic~s occurred in II of&? 14 patients. One or more 
adverse systemic effects (nausea, diarrhea, 
fever, eye swelling 
One or more adverse ca 
Tc interval and 
occurred in four 
Fig&! 3. The log dose-probit curves for quirtidine in combination 
with , rnexilefime in combination 
with monotherapy (dashed line) 
deter suppression f ventricular 
premature complexes. The dose-response relation can be linearized 
using probit (for probability) transformations. The customary mea- 
is the point on the log dose scale correspond- 
d 50% responding (right). The line describing 
the quinidine dose used in combination with mexiletine is left of the 
line describing quinidine monotberapy. From the theoretic line, the 
quinidine dose at which 50% respond after combination herapy is 
cl00 mg and after monotherapy is 390 mg every 8 h. 
9g (I 
z 
90 s 
80 Q 
50 2 
20 
5 
w 
IO ii 
tt! 
I 
100165 330 660 
DOSE (mg q8hl that for quinidine monotherapy. The criteria of =gO% SUP- 
Nausea 
Diarrhea 
Bradycardia 
< 30 beatslmin 
F 
C 
Insomnia 
Nervousness 
Dry mouth 
Eye swelling 
8 
3”f 
a*+ 
I IV 
Il*t 
2$ 
4 
*On combination quinidine-mexiletine crossover limb; iprobably mexilet- 
ct; Mikely related to quinidine or mexiletine. Pt = 
patient. 
ients co~~i~~ed taking conabi- 
after co 
g, one for 44 weeks and the 
nowledge ofthe relation between drug dose and e 
the key to making rational dosage decisions. 
antiarrhythmic agents, premarketing dose-ranging studies 
are performed to establish a reasonable initial dose. A basic 
principle is to start with the lowest dose likely to prove 
sufficiently effective. Recently, he U.S. Food and Drug 
Administration has encouraged premarketing strategies to 
define the low end of the dose-response curve. A major 
argument for investigating thelow end of the dose-response 
curve is that because drug-related a verse effects increase as 
ncreases, the risk/benefit 
ose-response curv 
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pression of ventrictdar p emature complexes during combi- 
nation therapy was reached in I3 of 14 patients compared 
with 5 of I5 during monotherapy. In addition, adverse effects 
occurred in 3 of I4 patients during combination therapy and 
in 10 of I5 during monotherapy. Adverse ffects attributed to
quinidine were frequent and occurred at even the lowest 
monotherapy dose. The quinidine dose used in combination 
with mexiletine to suppress ventricular premature corn-- 
plexes r80% in the combination limb was less than half that 
required in the monotherapy limb and significantly less than 
that previously reported (3,5,11). All patients except one 
responded at the lowest conventional quinidine dose in 
combination dictated by the protocol; however, itis theoret- 
ically possible that even lower quinidine or mexiletine doses 
could be effective (Fig. 3). 
Comparison f quinidine=mexiletine dose with that in other 
studies. Previous tudies (3-5) documenting the effective- 
ness of quinidine-mexiletine combination therapy utilized 
daily doses equivalent toor slightly less than that of conven- 
tional quinidine (200 to 400 mg every 6 h) or mexiietine (200 
to 400 mg every 8 II) monotherapy. Two clinical studies (3S) 
reported an average daily quinidine dose ranging from 824 to 
1,080 mg. Another study (I I) found the average daily quini- 
dine dose to be 1,643 mg. Similarly, in these studies (3,&l I) 
the daily mexiletine dose was also high, ranging from 636 to 
800 mg. In the present trial, daily doses were considerably 
lower (quinidine, 570 +- 87 mg; mexiletine, 450 2 60 mg). 
Comparabie suppression of ventricular premature com- 
plexes (88 ? 11%) and abolition of nonsustained ventricular 
tachycardia (100 + 1%) with that in studies using higher 
doses was observed. One explanation f r these findings is 
that the low end of the dose response for combination 
therapy islower than previously considered. Another possi- 
bility is that our study patients differ from patients previ- 
ously reported (3-S) in that they I) predominantly have 
cardiomyopathy or electrical bnormalities; 2) have normal 
ejection fraction; 3) have benign or potentially malignant 
ventricular rhythmias; and 4) had a 24 h ambulatory ECG 
rather than electrophysiologic testing to assess antiarrhyth- 
mic action. 
Because the low end of the dose-response curve of 
combination therapy for malignant ventricular arrhythmias 
has not been studied, it remains to be evaluated whether 
doses similar to those used here can effectively suppress 
sustained ventricular rhythmias. To date, no antiarrhyth- 
n:ic agent has been shown to reduce the incidence of fatal or 
ncnfatd cardiac arrest: therefore, it is not known whether 
the administration of low dose quinidine-mexiletine, or any 
other antiarrhythmic drug, is clinically relevant. However, 
low dose quinidine-mexiletine mayprovide an alternative for 
Patients who have symptomatic arrhythmias and find con- 
ventional or high doses of quinidine or mexiletine intolera- 
ble. Low dose quinidine-mexiletine combination therapy 
could also prove useful for patients with ventricular dysfunc- 
tion in whom some antiarrhythmic therapy may further 
depress cardiac function. One r port (11) indicates that daily 
doses of quinidine, 1,643 mg, plus mexiletine, 636 mg, do not 
depress left or right ventricular function at rest or during 
exercise. We anticipate that low dose quinidine-mexiletine 
would have a similar effect on ventricular function. 
Althollgh, a test of the eficacy of conventional mexiletbe 
doses was not attempted here, in three arlier trials (12-14), 
conventional daily doses of mexiletine, 600 to 1,200 mg, 
suppressed arrhythmia in conly 66% (l2), 54% (13) and 69% 
(14) of patients with symptomatic ventricular premature 
complexes and ventricular tachycardia. Moreover, in each 
trial, the criterion for efficacy was lower (that is, 50% in one 
trial [12] as assessed with ambulatory ECG and exercise 
testing and 70% in the others [ 13,141). Although the present 
trial did not have a mexiletine monotherapy limb, we used 
lower mexiletine doses than those the manufacturer recom- 
mends (15) or that have been extensively evaluated. 
Whether the more marked arrhythmia suppression during 
combination therapy could have been attributed solely to 
mexiletine, independent of low dose quinidine, was consid- 
ered. Although this possibility seems omewhat unlikely in 
view of only moderate efficacy reported in previous studies 
(12-14) with conventional mexiletine monotherapy com- 
pared with >80% suppression i  >80% of patients after low 
dose quinidine-mexiletine, further studies are required to 
test the efficacy of mexiletine, 100 to 150 mg three times 
daily. 
Eleetropharmacologlc effects. The electropharmacologic 
effects of combination quinidine-mexiletine have been xten- 
sively studied in a number of animal species (16-19) and 
humans (3-5). Studies of canine Purkinje fiber and rabbit 
ventricular muscle indicate that quinidine-mexiletine ex rts 
a synergistic effect by depressing q,,, to the same xtent as 
solutions with twice the quinidine concentration (16) and 
prolongs refractoriness (17) and infarct zone conduction time 
(18) more than monotherapy. These basic electrophysiologic 
studies (16-19) support observations in humans (3-5), in 
whom combination therapy prolongs ventricular tachycardia 
cycle length and refractory periods and prolongs conduction 
in dyskinetic zones of the left ventricle. The changes in 
conduction and refractoriness seen with quinidine-mexilet- 
ine are thought to be consistent with the modulated r ceptor 
hypothesis (20), wherein an agent such as mexiletine pro- 
vides added epression of early extrasystoles byblocking 
sodium channels not occupied by quinidine (21) vis a vi: 
different kinetics of interaction with the sodium channel. 
It has been suggested (3) that quinidine-mexiletine abol- 
ishes arrhythmias by prolonging conduction velocity in a 
reentrant circuit such that unidirectional block is converted 
to bidirectional b ock. Evidence for conduction delay is 
inferred from the ECG, on which prolongation of the cou- 
pling interval, s occurs with other type I agents uch as 
procainamide (22), has been observed. However, prolonga- 
JACC Vol. 15. No. 5 
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of low dose ~B~~~~~~e-~ex~~et~~e therapy in 
will have to address the issue of improv 
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